Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
Do you take any special treatment considerations for elderly patients diagnosed with collapsing FSGS?
Related Questions
What are some measures to prevent flares of loin pain-hematuria syndrome?
When would you consider a kidney biopsy in a patient with longstanding diabetes and hypertension (baseline creatinine 4-5, 4+ proteinuria) who was recently found to have dsDNA positivity?
Do you pursue a skin biopsy or kidney biopsy in patients whom you suspect have X-linked Alport syndrome?
How do you determine duration of therapy for patients who have responded well to voclosporin therapy?
In which patients with MGUS do you recommend a kidney biopsy to evaluate for MGRS?
Do you prefer a mycophenolate or tacrolimus based glucocorticoid-sparing regimen for patients with minimal change disease?
How do you choose between eculizumab and ravulizumab for patients with acute kidney injury from complement mediated thrombotic microangiopathy?
Do you think there would be benefit in using sparsentan over irbesartan for FSGS given a higher percentage of patients with partial remission of proteinuria on sparsentan despite no significant difference in eGFR slope in the DUPLEX Trial?
What is your approach to the management of secondary membranous nephropathy with nephrotic range proteinuria?
Would you treat a patient aggressively for lupus nephritis if they have persistent proteinuria over 1 gram but cannot get a timely kidney biopsy?
